Perspective Therapeutics (CATX) Enterprise Value (2010 - 2026)

Perspective Therapeutics has disclosed Enterprise Value across 17 years of filings, most recently posting -$487.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$487.9 million, down 28.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$487.9 million (down 28.72% YoY), and the FY2025 annual result was -$144.7 million, up 36.22% from the prior year.
• Enterprise Value came in at -$487.9 million for Q1 2026 at Perspective Therapeutics, down from -$144.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$9.2 million in Q4 2023 to a low of -$487.9 million in Q1 2026.
• The 5-year median for Enterprise Value is -$144.7 million (2025), against an average of -$167.9 million.
• Across the five-year window, Enterprise Value surged 78.89% in 2023 and tumbled 2356.33% in 2024, its largest moves.
• Perspective Therapeutics' Enterprise Value stood at -$43.8 million in 2022, then soared by 78.89% to -$9.2 million in 2023, then sank by 2356.33% to -$226.9 million in 2024, then surged by 36.22% to -$144.7 million in 2025, then sank by 237.06% to -$487.9 million in 2026.
• The last three Enterprise Value figures came in at -$487.9 million (Q1 2026), -$144.7 million (Q4 2025), and -$174.1 million (Q3 2025), per Business Quant data.